Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | CFD | P00746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772466 | 0.93 | AKR1C3 (0.46) | AKR1C3ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6771632 | 0.92 | AKR1C3 (0.41) | AKR1C3ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6765566 | 0.92 | AKR1C3 (0.45) | AKR1C3LMNAHTTALDH1A1KDM4E | |
| SCHEMBL6767472 | 0.92 | AKR1C3 (0.43) | AKR1C3CFDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7249486 | 0.92 | AKR1C3 (0.40) | AKR1C3CFDLMNAALDH1A1KDM4E | |
| SCHEMBL7012250 | 0.89 | ALDH1A1 (0.41) | AKR1C3ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL6765104 | 0.89 | KDM4E (0.40) | AKR1C3CFDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL7009025 | 0.88 | KDM4E (0.40) | AKR1C3CFDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6764933 | 0.88 | CNR2 (0.39) | AKR1C3CFDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6766548 | 0.87 | CFD (0.54) | CFDLMNAHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027885-B1 | Basic drug compositions with enhanced bioavailability | PFIZER PROD INC (US) | 2008-07-09 | — | — | EP | claimed |
| US-20040052845-A1 | Hydrogel-driven drug dosage form | BEND RESEARCH, INC. | 2004-03-18 | — | — | US | claimed |
| EP-1326587-A2 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030086972-A1 | Hydrogel-driven drug dosage form | BEND RESEARCH, INC. | 2003-05-08 | — | — | US | claimed |
| WO-2002011702-A2 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | PFIZER PRODUCTS INC. (GB) | 2002-02-14 | — | — | WO | claimed |
| US-11971402-B2 | Methods and reagents for determination and treatment of organotropic metastasis | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| EP-1970052-A2 | Basic drug compositions with enhanced bioavailability | Pfizer Products Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1027885-B1 | Basic drug compositions with enhanced bioavailability | PFIZER PROD INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20050049223-A1 | Basic drug compositions with enhanced bioavailability | BEND RESEARCH, INC. | 2005-03-03 | — | — | US | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20040052845-A1 | Hydrogel-driven drug dosage form | BEND RESEARCH, INC. | 2004-03-18 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1326587-A2 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030086972-A1 | Hydrogel-driven drug dosage form | BEND RESEARCH, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6548555-B1 | Solubility in small intestines; hydroxypropyl methyl cellulose acetate succinate polymer and zwitterion drug; | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002011702-A2 | HYDROGEL-DRIVEN DRUG DOSAGE FORM | PFIZER PRODUCTS INC. (GB) | 2002-02-14 | — | — | WO | disclosed |
| EP-1027885-A2 | Basic drug compositions with enhanced bioavailability | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | AKR1C3 180/4885CFD 3186/4885LMNA 957/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | AKR1C3 187/4885CFD 3094/4885LMNA 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.